Pharming regains U.S. rights to hereditary angioedema drug
By Nuala Moran
Wednesday, August 10, 2016
LONDON – Pharming Group NV has seized on Valeant Pharmaceuticals Inc.'s need to "stabilize" its organization and streamline the portfolio, taking back all U.S. rights to Ruconest in the treatment of acute HAE.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.